186 related articles for article (PubMed ID: 33191243)
41. Sequential use of hemoperfusion and single-pass albumin dialysis can safely reverse methotrexate nephrotoxicity.
Chan WK; Hui WF
Pediatr Nephrol; 2016 Oct; 31(10):1699-703. PubMed ID: 27335061
[TBL] [Abstract][Full Text] [Related]
42. Carboxypeptidase G2 rescue in a 79 year-old patient with cranial lymphoma after high-dose methotrexate induced acute renal failure.
Krackhardt A; Schwartz S; Korfel A; Thiel E
Leuk Lymphoma; 1999 Nov; 35(5-6):631-5. PubMed ID: 10609804
[TBL] [Abstract][Full Text] [Related]
43. Continuous plasma resin perfusion for detoxification of methotrexate.
Greil J; Wyss PA; Ludwig K; Bonakdar S; Scharf J; Beck JD; Ruder H
Eur J Pediatr; 1997 Jul; 156(7):533-6. PubMed ID: 9243235
[TBL] [Abstract][Full Text] [Related]
44. Carboxypeptidase G2 rescue after high-dose methotrexate.
DeAngelis LM; Tong WP; Lin S; Fleisher M; Bertino JR
J Clin Oncol; 1996 Jul; 14(7):2145-9. PubMed ID: 8683248
[TBL] [Abstract][Full Text] [Related]
45. Serum creatinine and creatinine clearance for predicting plasma methotrexate concentrations after high-dose methotrexate chemotherapy for the treatment for childhood lymphoblastic malignancies.
Xu WQ; Zhang LY; Chen XY; Pan BH; Mao JQ; Song H; Li JY; Tang YM
Cancer Chemother Pharmacol; 2014 Jan; 73(1):79-86. PubMed ID: 24158402
[TBL] [Abstract][Full Text] [Related]
46. [Carboxypeptidase-G2 administration after high-dose methotrexate. Treatment and drug interactions].
Cózar Olmo JA; Martínez Colmenero C; Peláez Pleguezuelos I; Leiva Gea I; López García AB; de la Cruz Moreno J
An Pediatr (Barc); 2009 Sep; 71(3):230-4. PubMed ID: 19617010
[TBL] [Abstract][Full Text] [Related]
47. High-dose cyclophosphamide-high-dose methotrexate with coordinated intrathecal therapy for advanced nonlymphoblastic lymphoma of childhood: results of a Pediatric Oncology Group study.
Sullivan MP; Brecher M; Ramirez I; Ragab A; Hvizdala E; Pullen J; Shuster J; Berard C; Crist W; Vietti T
Am J Pediatr Hematol Oncol; 1991; 13(3):288-95. PubMed ID: 1793154
[TBL] [Abstract][Full Text] [Related]
48. High-dose trimetrexate and minimal-dose leucovorin: a case for selective protection?
Hum M; Holcenberg JS; Tkaczewski I; Weaver JW; Wilson J; Kamen BA
Clin Cancer Res; 1998 Dec; 4(12):2981-4. PubMed ID: 9865909
[TBL] [Abstract][Full Text] [Related]
49. Leucovorin and maximum tolerated dose toxicity of methotrexate in rats.
Fuskevåg OM; Kristiansen C; Lindal S; Aarbakke J
Pediatr Hematol Oncol; 2000 Dec; 17(8):651-8. PubMed ID: 11127396
[TBL] [Abstract][Full Text] [Related]
50. Solitary serum methotrexate level 36 hours post high-dose methotrexate: A safe, efficacious, and cost-effective strategy to monitor methotrexate toxicities in childhood leukemia in resource-limited centers.
Khera S; Kapoor R; Pramanik SK
Pediatr Blood Cancer; 2020 Jul; 67(7):e28387. PubMed ID: 32400952
[TBL] [Abstract][Full Text] [Related]
51. [Management recommendations in patients with methotrexate intoxication].
Schellens JH; Beijnen JH
Ned Tijdschr Geneeskd; 2007 Feb; 151(6):337-41. PubMed ID: 17352296
[TBL] [Abstract][Full Text] [Related]
52. Delayed elimination of high-dose methotrexate and use of carboxypeptidase G2 in pediatric patients during treatment for acute lymphoblastic leukemia.
Svahn T; Mellgren K; Harila-Saari A; Åsberg A; Kanerva J; Jónsson Ó; Vaitkeviciene G; Stamm Mikkelssen T; Schmiegelow K; Heldrup J
Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 27966809
[TBL] [Abstract][Full Text] [Related]
53. Comparison of pharmacokinetics and toxicity after high-dose methotrexate treatments in children with acute lymphoblastic leukemia.
Csordas K; Hegyi M; Eipel OT; Muller J; Erdelyi DJ; Kovacs GT
Anticancer Drugs; 2013 Feb; 24(2):189-97. PubMed ID: 23187460
[TBL] [Abstract][Full Text] [Related]
54. Resumption of high-dose methotrexate after methotrexate-induced nephrotoxicity and carboxypeptidase G2 use.
Snyder RL
Am J Health Syst Pharm; 2007 Jun; 64(11):1163-9. PubMed ID: 17519458
[TBL] [Abstract][Full Text] [Related]
55. Bayesian population model of methotrexate to guide dosage adjustments for folate rescue in patients with breast cancer.
Monjanel-Mouterde S; Lejeune C; Ciccolini J; Merite N; Hadjaj D; Bonnier P; Piana P; Durand A
J Clin Pharm Ther; 2002 Jun; 27(3):189-95. PubMed ID: 12081632
[TBL] [Abstract][Full Text] [Related]
56. Successful rescue with leucovorin and thymidine in a patient with high-dose methotrexate induced acute renal failure.
van den Bongard HJ; Mathĵt RA; Boogerd W; Schornagel JH; Soesan M; Schellens JH; Beijnen JH
Cancer Chemother Pharmacol; 2001 Jun; 47(6):537-40. PubMed ID: 11459208
[TBL] [Abstract][Full Text] [Related]
57. [Correlation study of blood drug concentration and nephrotoxicity on high dose methotrexate therapy in suggestion of diagnosis and treatment of childhood acute lymphoblastic leukemia in the 4th revised edition].
Cheng DH; Lu H; Zou XQ
Zhonghua Er Ke Za Zhi; 2017 Oct; 55(10):771-774. PubMed ID: 29050116
[No Abstract] [Full Text] [Related]
58. Pharmacokinetics and pharmacogenetics of high-dose methotrexate in Chinese adult patients with non-Hodgkin lymphoma: a population analysis.
Yang L; Wu H; de Winter BCM; Sheng CC; Qiu HQ; Cheng Y; Chen J; Zhao QL; Huang J; Jiao Z; Xie RX
Cancer Chemother Pharmacol; 2020 May; 85(5):881-897. PubMed ID: 32246190
[TBL] [Abstract][Full Text] [Related]
59. Successful treatment of intrathecal methotrexate overdose with folinic acid rescue: a case report.
Riva L; Conter V; Rizzari C; Jankovic M; Sala A; Milani M
Acta Paediatr; 1999 Jul; 88(7):780-2. PubMed ID: 10447141
[TBL] [Abstract][Full Text] [Related]
60. The inability of oral leucovorin to elevate CSF 5-methyl-tetrahydrofolate following high dose intravenous methotrexate therapy.
Allen J; Rosen G; Juergens H; Mehta B
J Neurooncol; 1983; 1(1):39-44. PubMed ID: 6611387
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
